酪氨酸激酶抑制剂联合或不联合立体定向放射外科（SRS）治疗EGFR和ALK驱动型的NSCLC脑转移（TURBO-NSCLC）

文章预览

SCI 21 August 2024 Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC) （Journal of clinical oncology；IF：42.1） Pike LRG, Miao E, Boe LA, Patil T, Imber BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, Chiang V, Grant M, Goldberg SB, Palmer JD, Prasad RN, Wang TJC, Lee A, Shu CA, Chen LN, Thomas NJ, Braunstein SE, Kavanagh BD, Camidge DR, Rusthoven CG. Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene-Driven Non-Small Cell Lung Cancer (TURBO-NSCLC). J Clin Oncol. 2024 Jul 24:JCO2302668. doi: 10.1200/JCO.23.02668. Epub ahead of print. PMID: 39047224. CORRESPONDING AUTHOR ：Chad G. Rusthoven, MD Department of Radiation Oncology, University of Colorado, Aurora, CO. e-mail: chad.rusthoven@cuanschutz.ed u. Purpose 目的 Newer-generation tyrosine kinase inhibitors (TKIs) for non-small ………………………………